Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy.

MLA

Pfütze, Katrin, et al. “Methylation Status at HYAL2 Predicts Overall and Progression-Free Survival of Colon Cancer Patients under 5-FU Chemotherapy.” Genomics, vol. 106, no. 6, Dec. 2015, pp. 348–54. EBSCOhost, https://doi.org/10.1016/j.ygeno.2015.10.002.

APA

Pfütze, K., Benner, A., Hoffmeister, M., Jansen, L., Yang, R., Bläker, H., Herpel, E., Ulrich, A., Ulrich, C. M., Chang-Claude, J., Brenner, H., & Burwinkel, B. (2015). Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy. Genomics, 106(6), 348–354. https://doi.org/10.1016/j.ygeno.2015.10.002

Chicago

Pfütze, Katrin, Axel Benner, Michael Hoffmeister, Lina Jansen, Rongxi Yang, Hendrik Bläker, Esther Herpel, et al. 2015. “Methylation Status at HYAL2 Predicts Overall and Progression-Free Survival of Colon Cancer Patients under 5-FU Chemotherapy.” Genomics 106 (6): 348–54. doi:10.1016/j.ygeno.2015.10.002.